SOCRA CCRP Practice Exam Quiz

Reviewed by Editorial Team
The ProProfs editorial team is comprised of experienced subject matter experts. They've collectively created over 10,000 quizzes and lessons, serving over 100 million users. Our team includes in-house content moderators and subject matter experts, as well as a global network of rigorously trained contributors. All adhere to our comprehensive editorial guidelines, ensuring the delivery of high-quality content.
Learn about Our Editorial Process
| By Jessica
J
Jessica
Community Contributor
Quizzes Created: 1 | Total Attempts: 19,990
| Attempts: 20,234
SettingsSettings
Please wait...
  • 1/50 Questions

    During the clinical trial, regulations require that a subject be given the right to...

    • Travel 
    • Withdraw at any time
    • Get financial compensation
    • Speak to a sponsors attorney 
Please wait...
About This Quiz

Prepare thoroughly for the SOCRA Certified Clinical Research Professional (CCRP) exam with our expertly crafted Practice Exam Quiz. Designed to replicate the format and rigor of the real exam, this quiz is an essential tool for gauging your readiness. Covering all crucial topics in clinical research, it’s perfect for both aspiring CCRPs seeking certification and seasoned professionals wanting to refresh See moretheir knowledge.

By taking this quiz, you can evaluate your understanding, pinpoint areas that need improvement, and build the confidence needed to excel. Whether you are just starting out in clinical research or are an experienced researcher looking to validate your expertise, our Practice Exam Quiz will help guide you toward success in your certification journey.

SOCRA CCRP Practice Exam Quiz - Quiz

Quiz Preview

  • 2. 

    *Which of the following is the proper way to make a correction to a CRF?

    • Completely blacken the incorrect entry and then enter the correct information

    • Back date the corrected entry with the date of the original entry

    • Initial using the initials of the sponsor’s representative who reviewed the change

    • Add the initials of the person making the change, the date of the change, and, if necessary, a brief explanation of the change

    Correct Answer
    A. Add the initials of the person making the change, the date of the change, and, if necessary, a brief explanation of the change
    Explanation
    To make a correction to a CRF, the proper way is to add the initials of the person making the change, the date of the change, and, if necessary, a brief explanation of the change. This ensures that the correction is properly documented and attributed to the person responsible for making the change. It also provides clarity and transparency regarding the reason for the correction, if needed.

    Rate this question:

  • 3. 

    *A purpose of monitoring clinical trials is to verify that:

    • The rights, safety, and well-being of human subjects are protected

    • Investigators receive adequate payment for their participation in the clinical trial

    • The investigator has received annual reports from the sponsor

    • The regulatory agency has received all case history information of subjects enrolled on the clinical trial

    Correct Answer
    A. The rights, safety, and well-being of human subjects are protected
    Explanation
    The purpose of monitoring clinical trials is to ensure that the rights, safety, and well-being of human subjects are protected. This involves regularly assessing and evaluating the trial to identify any potential risks or adverse events that may occur during the study. Monitoring also ensures that the trial is being conducted in accordance with ethical guidelines and regulatory requirements to minimize any harm to the participants. By verifying that these protections are in place, the monitoring process helps to maintain the integrity and validity of the clinical trial.

    Rate this question:

  • 4. 

    *The responsibility for ensuring that the investigator understands a clinical trial lies with:

    • FDA

    • IRB

    • Sponsor 

    • Coordinator 

    Correct Answer
    A. Sponsor 
    Explanation
    The sponsor is responsible for ensuring that the investigator understands a clinical trial. This includes providing the necessary information and training to the investigator, as well as ensuring that the investigator is aware of and follows all applicable regulations and guidelines. The sponsor also plays a role in monitoring the progress of the trial and addressing any issues or concerns that may arise.

    Rate this question:

  • 5. 

    Only the principal investigator is allowed to transcribe data from the source document to the CRF? 

    • True

    • False

    Correct Answer
    A. False
    Explanation
    False. The principle investigator is not the only person allowed to transcribe data from the source document to the CRF. Other trained and authorized personnel, such as research assistants or data managers, may also be involved in this process. The principle investigator may oversee the data transcription, but it is not exclusively their responsibility.

    Rate this question:

  • 6. 

    Minimal risk is defined as "the magnitude of harm that a subject would encounter is not exceeded by those ordinarily encountered in daily life".

    • True

    • False

    Correct Answer
    A. True
    Explanation
    The statement is true because minimal risk refers to the level of harm that a subject may encounter during a study, and this harm should not exceed the risks that individuals typically face in their everyday lives. In other words, the potential harm to participants should be no greater than what they would normally encounter in their daily activities. This ensures that the study does not pose an excessive risk to the participants' well-being.

    Rate this question:

  • 7. 

    The Food and Drug Administration (FDA) conducts drug risk assessments by considering which of the following?

    • There are a sufficient number of people needing the drug.

    • The benefits of the drug outweigh the known and potential risk of the drug 

    • The side-effects of the drug is measurable 

    • The sponsor is able to financially support the research 

    Correct Answer
    A. The benefits of the drug outweigh the known and potential risk of the drug 
    Explanation
    When assessing drug risks, the FDA primarily focuses on whether the benefits of a drug outweigh its known and potential risks. This risk-benefit analysis is crucial for determining whether a drug should be approved for public use. The other factors, while important in different contexts, do not play a central role in the FDA's risk assessment process.

    Rate this question:

  • 8. 

    *The IRB must determine that requirements for permission by parents or guardians and assent by children are met.

    • True

    • False

    Correct Answer
    A. True
    Explanation
    True. The IRB ensures that parental/guardian permission and child assent requirements are met in pediatric research, as per federal regulations. These requirements vary based on the research risk level and the child's age, helping to protect children's rights, safety, and well-being while considering their developmental and emotional needs.

    Rate this question:

  • 9. 

    The 3 fundamental ethical principles for human subjects' in research are:

    • Respect for persons, beneficence, justice

    • Respect for subjects, their safety and their time

    • Respect for sponsor, IRB and FDA guidelines 

    • Respect for data, welfare and discovery 

    Correct Answer
    A. Respect for persons, beneficence, justice
    Explanation
    The 3 fundamental ethical principles for human subjects in research are respect for persons, beneficence, and justice. These principles emphasize the importance of treating individuals with dignity and autonomy, ensuring their well-being and minimizing harm, and promoting fairness and equity in the distribution of research benefits and burdens. By adhering to these principles, researchers can ensure that their studies are conducted ethically and that the rights and welfare of the participants are protected.

    Rate this question:

  • 10. 

    The objective of the ICH GCP Guideline is to provide a unified standard for the European Union (EU), Japan, and the United States to facilitate the mutual acceptance of clinical data by the regulatory authorities in these jurisdictions.

    • True

    • False

    Correct Answer
    A. True
    Explanation
    The ICH GCP Guideline aims to establish a common standard for clinical data acceptance by regulatory authorities in the EU, Japan, and the United States. By providing a unified framework, it facilitates the mutual recognition and acceptance of clinical data across these jurisdictions. This helps streamline the regulatory process, ensuring that clinical trials conducted in these regions meet consistent quality standards and can be relied upon for decision-making purposes. Therefore, the statement "True" accurately reflects the objective of the ICH GCP Guideline.

    Rate this question:

  • 11. 

    Proper preparations should be made and adequate facilities provided to protect the experimental subject against even the remotest possibility of

    • Injury and hospitalization

    • Financial hardship

    • Concern

    • Injury, disability or death 

    Correct Answer
    A. Injury, disability or death 
    Explanation
    It is important to make proper preparations and provide adequate facilities to protect the experimental subject from any harm or danger. This includes ensuring their safety and well-being to prevent any possibility of injury, disability, or even death. The answer choice "Injury, disability or death" encompasses the most severe consequences that could potentially occur if proper precautions are not taken.

    Rate this question:

  • 12. 

    *With respect to IRB/IEC membership, both the FDA and the ICH require that

    • A majority of the members' primary area of interest is in a scientific area

    • At least one member holds a Ph.D. degree or equivalent

    • At least one member's primary area of interest is in a nonscientific area

    • A majority of the members are from or have ties to the institution of record

    Correct Answer
    A. At least one member's primary area of interest is in a nonscientific area
    Explanation
    Both the FDA and the ICH require that at least one member's primary area of interest is in a nonscientific area. This means that there should be at least one member on the IRB/IEC whose expertise is not solely focused on scientific matters. This requirement ensures that the review board has a diverse range of perspectives and can consider the ethical, social, and cultural implications of the research being conducted. It helps to prevent any potential biases or conflicts of interest that may arise if all members have a purely scientific background.

    Rate this question:

  • 13. 

    *In a non-emergency situation, under which of the following conditions, if any, may subjects be enrolled into a study prior to IRB/IEC approval?

    • The investigator provides his/her written approval

    • The study drug has an FDA approved marketing application

    • The FDA provides written approval of the IND

    • Subjects cannot be enrolled until IRB/IEC approval has been obtained 

    Correct Answer
    A. Subjects cannot be enrolled until IRB/IEC approval has been obtained 
    Explanation
    In a non-emergency situation, subjects cannot be enrolled into a study prior to IRB/IEC approval. This means that even if the investigator provides their written approval or if the study drug has an FDA approved marketing application, subjects still cannot be enrolled until the necessary IRB/IEC approval has been obtained. The FDA providing written approval of the IND also does not allow for subjects to be enrolled prior to IRB/IEC approval.

    Rate this question:

  • 14. 

    *A subject has been enrolled on a study and was randomized to the non-treatment arm. The protocol outlines study procedures for all subjects to be performed within one week of enrollment. Which of the following statements about this case is correct?

    • This subject does not need to undergo any of the study procedures since the subject is enrolled on the non-treatment arm

    • This subject should undergo all study procedures as outlined in the protocol

    • This subject only needs to undergo the study procedures that pertain specifically to the subject

    • This subject can undergo the study procedures whenever it is convenient

    Correct Answer
    A. This subject should undergo all study procedures as outlined in the protocol
    Explanation
    The correct answer is that this subject should undergo all study procedures as outlined in the protocol. Regardless of being randomized to the non-treatment arm, the protocol states that all subjects should undergo the study procedures within one week of enrollment. Therefore, this subject is still required to follow the protocol and complete all study procedures.

    Rate this question:

  • 15. 

    *What is the minimum number of IRB members?

    • 3

    • 5

    • 6

    • 10

    Correct Answer
    A. 5
    Explanation
    The minimum number of IRB members is 5 because having a minimum of 5 members ensures diversity and represents different perspectives and expertise. This allows for comprehensive review and evaluation of research proposals, ensuring ethical considerations are adequately addressed. With fewer than 5 members, there may not be enough diversity and expertise to effectively assess the ethical implications of the research.

    Rate this question:

  • 16. 

    Per 21 CFR Part 312, who is required to sign a 1572 Statement of Investigator form?

    • The investigator

    • The coordinator 

    • The investigator and the coordinator 

    • Anyone substantially involved in the study 

    Correct Answer
    A. The investigator
    Explanation
    Per 21 CFR Part 312, the investigator is required to sign the 1572 Statement of Investigator form. This form, officially known as Form FDA 1572, is a crucial document for clinical trials involving investigational new drugs, biologics, or medical devices in the United States. By signing Form 1572, the investigator commits to conducting the study according to the approved protocol, relevant regulations, and Good Clinical Practice (GCP) guidelines. The form also collects essential information about the investigator's qualifications, the study site, and the study itself. While the investigator is the primary individual required to sign the form, other members of the research team, such as study coordinators, may also be involved in providing relevant information or supporting the investigator throughout the study. However, the responsibility for signing the 1572 Statement of Investigator form ultimately lies with the investigator.

    Rate this question:

  • 17. 

    Form___________ is the investigator statement.

    • 1571

    • 1572

    • 3500

    • 3500A

    Correct Answer
    A. 1572
    Explanation
    The correct form is Form FDA 1572. Form 1572, also known as the "Statement of Investigator," is a document that must be completed by clinical investigators participating in research studies involving investigational new drugs, biologics, or medical devices in the United States. The purpose of this form is to provide the Food and Drug Administration (FDA) with essential information about the investigator's qualifications, the study site, and the study itself. By signing Form 1572, investigators commit to conducting the study in accordance with the approved protocol, relevant regulations, and Good Clinical Practice (GCP) guidelines. This form plays a crucial role in ensuring the ethical conduct of clinical trials and the protection of human subjects.

    Rate this question:

  • 18. 

    This form is used for the mandatory reporting of serious adverse events:

    • 1571

    • 1572

    • 3500

    • 3500A

    Correct Answer
    A. 3500A
    Explanation
    Form FDA 3500A is used for the mandatory reporting of serious adverse events, product problems, and medication errors associated with FDA-regulated products, such as drugs, biologics, and medical devices. This form is primarily intended for use by healthcare professionals, healthcare facilities, manufacturers, and importers to report serious events that occur during the use of these products. Reporting such events is essential to help the FDA monitor product safety, identify potential risks, and take appropriate actions to protect public health, including product label changes, safety warnings, or product recalls.

    Rate this question:

  • 19. 

    The contents of a Protocol should generally contain:

    • Trial objectives and purpose

    • Assessment of efficacy

    • Data handling and record keeping

    • All of the above 

    • Only A & C

    Correct Answer
    A. All of the above 
    Explanation
    The contents of a protocol should generally include the trial objectives and purpose, assessment of efficacy, and data handling and record keeping. Including the trial objectives and purpose helps to clearly define the goals and intentions of the study. Assessment of efficacy is crucial in determining the effectiveness of the intervention being studied. Data handling and record keeping ensure that all data collected during the trial is properly documented and organized for analysis. Therefore, all of the above options are necessary components of a protocol.

    Rate this question:

  • 20. 

    *Significant risk device is defined as an investigational device that is:

    • Intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a subject.

    • Purported or represented to be for a use in supporting or sustaining human life and presents a potential risk to the health, safety, or welfare of a subject.

    • For a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health and presents a potential for serious risk to the health, safety, or welfare of a subject.

    • All the above

    Correct Answer
    A. All the above
    Explanation
    The correct answer is "All the above" because all three options listed in the question describe the criteria for a device to be considered a significant risk device. A significant risk device is one that is intended as an implant and presents a potential for serious risk to the subject's health, safety, or welfare, or is purported to be for a use in supporting or sustaining human life and presents a potential risk, or is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health and presents a potential for serious risk.

    Rate this question:

  • 21. 

    When a short form is used for Informed Consent, the witness must sign either the short form or the summary.

    • True

    • False

    Correct Answer
    A. False
    Explanation
    According to regulations and best practices, the witness must sign both the short form and the summary when a short form is used for informed consent.

     

    Here's a breakdown of the correct process:

     

    Short Form: The short form is a translated document summarizing the essential elements of informed consent in the subject's preferred language.

    Written Summary: This is a detailed document in English that outlines all aspects of the informed consent process.

    Witness: An individual (over 18, fluent in both languages, not involved in the study) witnesses the researcher obtaining consent from the subject.

    Signing: After the subject understands and agrees to participate, they sign the short form. The witness then signs both the short form and the written summary to confirm they witnessed the process and the subject's agreement.

    Therefore, it's crucial for both the short form and the summary to be signed by the witness for proper documentation and ethical research practice.

    Rate this question:

  • 22. 

    An investigational drug can be exported from the U.S., if

    • Permission is granted by Congress 

    • The intended recipient is a US pharmacy

    • The importer is a foreign pharmacy inspected and approved by the FDA 

    • Approval is granted after a written request is submitted to the FDAs International Affairs Staff Associate Commissioner. 

    • The drug is for investigational use only and goes directly to a potential patient 

    Correct Answer
    A. Approval is granted after a written request is submitted to the FDAs International Affairs Staff Associate Commissioner. 
    Explanation
    The correct answer is "Approval is granted after a written request is submitted to the FDAs International Affairs Staff Associate Commissioner." This means that in order for an investigational drug to be exported from the U.S., a written request must be submitted to the FDAs International Affairs Staff Associate Commissioner and approval must be granted. This suggests that there is a regulatory process in place to ensure that the exportation of investigational drugs is done in a controlled and monitored manner.

    Rate this question:

  • 23. 

    In accordance with regulations, before implementation, the informed consent document must be approved by the:

    • Sponsor

    • Investigator

    • IRB or IEC

    • A, B & C

    • B & C only 

    Correct Answer
    A. IRB or IEC
    Explanation
    In accordance with regulations, the informed consent document must be approved by the IRB (Institutional Review Board) or IEC (Independent Ethics Committee). These bodies are responsible for reviewing research protocols and ensuring that the rights and welfare of study participants are protected. The sponsor and investigator may also be involved in the approval process, but the ultimate authority lies with the IRB or IEC. Therefore, the correct answer is IRB or IEC.

    Rate this question:

  • 24. 

    The Code of Federal Regulations part 50, 56 and 312 (among others) are designed to ensure the safety of clinical testing and the safety of products following a marketing approval.

    • True

    • False

    Correct Answer
    A. True
    Explanation
    The Code of Federal Regulations (CFR) contains specific parts that address the safety and regulation of clinical trials and drug products in the United States.

    21 CFR Part 50: This section outlines the regulations for the protection of human subjects involved in clinical trials. It covers informed consent, institutional review boards (IRBs), and the responsibilities of researchers and sponsors.


    21 CFR Part 56: This part focuses on institutional review boards (IRBs), which are independent committees responsible for reviewing and approving research involving human subjects to ensure their safety and welfare.


    21 CFR Part 312: This section provides regulations for the investigational new drug (IND) application process. It outlines the requirements for conducting clinical trials with new drugs and the procedures for obtaining FDA approval to market a new drug.

    These regulations are essential for protecting the rights and safety of clinical trial participants and ensuring the quality and safety of drugs available to the public. 

    Rate this question:

  • 25. 

    What is 45 CFR Part 46?

    • HHS - Protection of Human Subjects

    • FDA - Protection of Human Subjects

    • HHS - Protection of Children 

    • HHS - Protection of Research Participants 

    Correct Answer
    A. HHS - Protection of Human Subjects
    Explanation
    45 CFR Part 46 refers to the Code of Federal Regulations (CFR) that outlines the protection of human subjects in research activities conducted or supported by the U.S. Department of Health and Human Services (HHS). Specifically, it is titled "Protection of Human Subjects." These regulations are based on the ethical principles outlined in the Belmont Report and provide a framework for the conduct of research involving human subjects. The regulations cover various aspects of research, including the requirement for Institutional Review Board (IRB) review and approval, informed consent procedures, and the protection of vulnerable populations, such as children, pregnant women, and prisoners. Compliance with 45 CFR Part 46 is essential for institutions and researchers involved in HHS-funded or conducted research to ensure the ethical treatment and safety of human subjects.

    Rate this question:

  • 26. 

    The international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects is known as...

    • The ICH

    • Good Clinical Practices (GCP)

    • The Declaration of Helsinki

    • Fundamental Ethical Principles (FEP)

    Correct Answer
    A. Good Clinical Practices (GCP)
    Explanation
    Good Clinical Practices (GCP) is the international ethical and scientific quality standard for designing, conducting, recording, and reporting trials involving human subjects. GCP ensures that the rights, safety, and well-being of the participants are protected and that the data generated from the trials are reliable and credible. It provides guidelines on the ethical considerations, study design, participant recruitment, informed consent process, data collection and management, safety monitoring, and reporting of results. GCP is widely recognized and followed by regulatory authorities, research institutions, and pharmaceutical companies to ensure the highest standards of research integrity and participant protection.

    Rate this question:

  • 27. 

    *In general, an AE observed during the conduct of a study should be considered an unanticipated problem involving risk to human subjects, and reported to the IRB, only if it were _________.

    • Expected

    • Serious

    • Would have implications for the conduct of the study

    • B & C

    • A, B & C 

    Correct Answer
    A. B & C
    Explanation
    An adverse event (AE) observed during a study should be considered an unanticipated problem involving risk to human subjects and reported to the IRB if it is serious and would have implications for the conduct of the study. This means that if the AE is both serious and would affect the study, it should be reported to the IRB. The answer B & C correctly identifies these criteria.

    Rate this question:

  • 28. 

    According to 21 CFR 312.56, if a sponsor finds an investigator is non-compliant with a clinical protocol or approved investigational plan, the sponsor must:

    • Report the investigator to the IRB once it becomes aware 

    • Bring the investigator into compliance

    • Immediately close that investigators site

    • None of the above 

    Correct Answer
    A. Bring the investigator into compliance
    Explanation
    According to 21 CFR 312.56, if a sponsor finds an investigator to be non-compliant with a clinical protocol or an approved investigational plan, the sponsor must:Bring the investigator into complianceThe regulation requires the sponsor to ensure that the investigator either complies with the protocol or provides a sufficient explanation for the deviation. The sponsor may terminate the investigator's participation if compliance cannot be achieved. Reporting the investigator to the IRB or closing the investigator's site might be necessary steps, but the primary action required by the regulation is to bring the investigator into compliance.

    Rate this question:

  • 29. 

    Who monitors the progress of all clinical trial investigations being conducted under an IND?

    • Principal Investigator

    • IRB

    • Sponsor

    • CRO

    Correct Answer
    A. Sponsor
    Explanation
    The sponsor is responsible for monitoring the progress of all clinical trial investigations being conducted under an IND. They oversee the trial and ensure that it is being conducted according to the protocol, regulations, and ethical guidelines. The sponsor is typically a pharmaceutical company, government agency, or academic institution that initiates and funds the clinical trial. They play a crucial role in ensuring the safety and efficacy of the investigational product and have the ultimate responsibility for the trial's success.

    Rate this question:

  • 30. 

    This form is used for the voluntary reporting of adverse events and product problems: 

    • 1571

    • 1572

    • 3500

    • 3500A

    Correct Answer
    A. 3500
    Explanation
    The correct form is Form FDA 3500. Form FDA 3500, also known as the "Voluntary Adverse Event Report," is used by healthcare professionals, consumers, and patients to voluntarily report adverse events and product problems related to drugs, biologics, medical devices, dietary supplements, and other FDA-regulated products. Reporting adverse events can help the FDA identify potential safety concerns, monitor product safety, and take appropriate actions to protect public health, such as issuing warnings or requiring label changes.

    Rate this question:

  • 31. 

    The World Medical Association (WMA) ethical principles for medical research involving human subjects is called...

    • The Belmont Report

    • The National Research Act

    • The Nuremberg Code

    • The Declaration of Helsinki 

    Correct Answer
    A. The Declaration of Helsinki 
    Explanation
    The Declaration of Helsinki is a set of ethical principles for medical research involving human subjects, established by the World Medical Association (WMA). It provides guidelines for researchers to ensure the protection and well-being of human participants in research studies. The Belmont Report, the National Research Act, and the Nuremberg Code are also important documents related to research ethics, but they are not specifically associated with the WMA or medical research involving human subjects.

    Rate this question:

  • 32. 

    Identify the manner in which the informed consent form (ICF) can be presented to the subject.

    • ICF can be read to the subject of the LAR

    • ICF is handed to the subject to read and sign on their own in private

    • ICF is delivered via FedEx with a return stamped envelope 

    • ICF must be delivered to the subject or LAR electronically with a read receipt requested 

    Correct Answer
    A. ICF can be read to the subject of the LAR
    Explanation
    Reading the informed consent form (ICF) to the subject or their legally authorized representative (LAR) is a common practice, particularly in cases where the subject may have difficulty reading due to various reasons such as poor eyesight, illiteracy, or cognitive impairments. This method ensures that the subject or LAR fully understands the content and implications of the consent they are giving. It also allows for immediate clarification of any questions or concerns. This approach is in line with ethical standards which emphasize that the process of obtaining informed consent must ensure comprehension and voluntariness. Other methods listed, like mailing the ICF or leaving the subject to read it alone, may not adequately ensure understanding and are less personal, potentially compromising the integrity of the informed consent process.

    Rate this question:

  • 33. 

    The clinical investigator will update the financial disclosure information if any relevant changes occur during the investigation's course and for _______ following the study's completion.

    • 6 months

    • 1 year

    • 2 years 

    • 5 years 

    Correct Answer
    A. 1 year
    Explanation
    The clinical investigator is required to update the financial disclosure information if any relevant changes occur during the investigation's course and for 1 year following the study's completion. This is important to ensure transparency and integrity in the research process and to identify any potential conflicts of interest that may arise. By updating the financial disclosure information for 1 year, it allows for a sufficient period of time to capture any changes that may occur after the study has ended.

    Rate this question:

  • 34. 

    Per 21 CFR Part 312, the sponsor must notify FDA and all participating investigators in an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. 

    • True

    • False

    Correct Answer
    A. True
    Explanation
    Study 21 CFR 312.32(c)(1)

    Rate this question:

  • 35. 

    What is covered in 21CFR50 Subpart B?

    • Informed consent of Human Subjects

    • IRB Functions and Operations

    • Records and Reports 

    • Additional Safeguards for Children in Clinical Investigations 

    Correct Answer
    A. Informed consent of Human Subjects
    Explanation
    21CFR50 Subpart B covers the informed consent of human subjects. This means that it includes the regulations and guidelines related to obtaining informed consent from individuals who participate in clinical investigations. Informed consent ensures that participants are fully aware of the purpose, risks, and benefits of the study before they decide to participate. It also ensures that participants have the right to withdraw from the study at any time. This subpart outlines the specific requirements and procedures that must be followed to obtain informed consent from human subjects.

    Rate this question:

  • 36. 

    Which signatures are required by FDA regulation to be on the consent form?

    • The investigator

    • The subject

    • The investigator and the suject

    • The subject and a witness 

    Correct Answer
    A. The subject
    Explanation
    FDA regulations require only the subject's (or their legally authorized representative's) signature on the consent form. The signature indicates voluntary agreement to participate after receiving the necessary information. In practice, the investigator often signs as well, confirming they explained the study and obtained informed consent.

    Rate this question:

  • 37. 

    The Code of Federal Regulations that applies to Investigational New Drug Applications is 21CFR812.

    • True

    • False

    Correct Answer
    A. False
    Explanation
    The statement is false. The Code of Federal Regulations that applies to Investigational New Drug (IND) Applications is 21 CFR Part 312, not 21 CFR 812. 21 CFR Part 312 provides the regulations and guidelines for obtaining and maintaining an IND, which is required for the study of investigational new drugs in the United States. This part covers the requirements for submitting an IND application, the responsibilities of sponsors and investigators, the protection of human subjects, and the monitoring and reporting of adverse events, among other topics. Compliance with these regulations is crucial for ensuring the ethical conduct of clinical trials and the safety of participants involved in the testing of new drug candidates.

    Rate this question:

  • 38. 

    After completion of the investigation, sponsor shall provide the investigator with a final report.

    • True

    • False

    Correct Answer
    A. True
    Explanation
    After the completion of a clinical investigation, the sponsor is required to provide the investigator with a final report. This report summarizes the findings, conclusions, and any outcomes from the study, ensuring that both the investigator and sponsor have a complete understanding of the results. It is a key part of clinical research documentation and ensures transparency, accountability, and proper closure of the study in compliance with regulatory standards.

    Rate this question:

  • 39. 

    The Code of Federal Regulations that applies to Institutional Review Boards is:

    • 45CFR46

    • 21CFR312

    • 21CFR50

    • 21CFR56

    Correct Answer
    A. 21CFR56
    Explanation
    The correct answer is 21CFR56 because it refers to the Code of Federal Regulations that applies to Institutional Review Boards. The other options, 45CFR46, 21CFR312, and 21CFR50, do not specifically pertain to Institutional Review Boards.

    Rate this question:

  • 40. 

    Once the sponsor evaluates data from a clinical trial and decides the drug presents an immeasurable and significant risk to the subjects; the sponsor has _____________ to discontinue the study.

    • 24 hours

    • 48 hours

    • 3 WD

    • 5 WD

    Correct Answer
    A. 5 WD
    Explanation
    Although the specific regulations may vary by country and regulatory body, a common timeframe for a sponsor to report significant safety issues and make necessary changes to a clinical trial, including discontinuation, is within 5 working days (WD). In the event that a drug presents an immeasurable and significant risk to the subjects, the sponsor should work expeditiously to gather the necessary information and notify the appropriate parties, such as ethics committees and regulatory authorities, within this timeframe. The sponsor should also take prompt action to protect the safety and well-being of the subjects, which may include discontinuing the study or making significant modifications to the protocol.

    Rate this question:

  • 41. 

    Which of the following is a key responsibility of a Clinical Research Coordinator (CRC) in ensuring compliance with Good Clinical Practice (GCP)?

    • Developing the study protocol 

    • Monitoring the data quality independently

    • Managing the day-to-day operations of a clinical trial 

    • Issuing payments to participants

    Correct Answer
    A. Managing the day-to-day operations of a clinical trial 
    Explanation
    A Clinical Research Coordinator (CRC) is primarily responsible for the daily management of clinical trials, which includes tasks such as participant recruitment, informed consent process, data collection, and ensuring adherence to the study protocol and regulatory requirements. This role ensures compliance with Good Clinical Practice (GCP) guidelines.

    Rate this question:

  • 42. 

    Each IRB that reviews studies involving children as subjects is covered by:

    • 21CFR 56, Subpart A

    • 21CFR 56, Subpart B

    • 21CFR 50, Subpart D

    • 21CFR 56, Subpart C

    Correct Answer
    A. 21CFR 50, Subpart D
    Explanation
    21 CFR 50, Subpart D- This section specifically provides "Additional Safeguards for Children in Clinical Investigations." It includes provisions that ensure extra protection for children involved in research, encompassing all necessary regulatory aspects to safeguard children’s welfare in clinical studies.

    Rate this question:

  • 43. 

    A Short Form informed consent is a written summary of the ICF that is not to exceed one page.

    • True

    • False

    Correct Answer
    A. False
    Explanation
    The statement is false. Although a Short Form informed consent is indeed a written summary of the full informed consent form (ICF), it is not necessarily limited to one page. The purpose of a Short Form informed consent is to provide a simplified, easily understandable version of the full ICF, focusing on the key information that potential research subjects need to make an informed decision about participating in a study.The Short Form typically includes a description of the study's purpose, procedures, risks, and benefits, as well as the subject's rights and responsibilities. It may also include contact information for the investigator or research team and a statement that the subject voluntarily agrees to participate.The Short Form informed consent is often used in situations where the full ICF is too complex or lengthy for the target population, such as when working with individuals who may have difficulty understanding the full document due to language barriers, cognitive impairments, or other factors. The Short Form must be accompanied by an oral presentation of the complete informed consent information, and a witness should be present to attest that the oral presentation occurred and that the subject understood the information. Both the subject and the witness must sign the Short Form to document their agreement to participate in the research.

    Rate this question:

  • 44. 

    What topic is covered in 45CFR46 Subpart B?

    • Additional Safeguards and Protections

    • Additional Protection for Prisoners and Vulnerable Subjects

    • Additional Protection for Children and Unborn Fetuses 

    • Additional Protections for Pregnant Women, Human Fetuses, and Neonates Involved in Research

    Correct Answer
    A. Additional Protections for Pregnant Women, Human Fetuses, and Neonates Involved in Research
    Explanation
    45 CFR 46 Subpart B, titled "Additional Protections for Pregnant Women, Human Fetuses, and Neonates Involved in Research," specifically addresses the ethical guidelines and additional safeguards and protections for research involving pregnant women, human fetuses, and neonates. This subpart outlines the regulatory requirements and considerations to ensure the well-being and safety of these vulnerable populations when they participate in research studies. It includes detailed rules and procedures to protect the rights and welfare of pregnant women and their unborn fetuses, as well as neonates involved in research activities.

    Rate this question:

  • 45. 

    When using the short form informed consent, the witness and the person actually obtaining the consent from the subject shall each sign the short form in addition to the summary.

    • True

    • False

    Correct Answer
    A. False
    Explanation
    Study 21 CFR 50.27 (2) -The witness shall sign BOTH the short form and summary. Person actually obtaining consent shall sign ONLY a copy of the summary. (Subject ONLY has to sign the short form).

    Rate this question:

  • 46. 

    FDA may waive any of the requirements contained in the regulations, including the requirements for IRB review.

    • True

    • False

    Correct Answer
    A. True
    Explanation
    The FDA can waive regulations, including IRB review, if it's in the public's best interest or necessary to protect subjects' rights and welfare. This might occur in emergencies where IRB review delays treatment for life-threatening conditions. The FDA considers various factors to ensure ethical principles are maintained and subjects' rights are safeguarded. Waivers are granted cautiously to maintain the integrity of research and participant safety.

    Rate this question:

  • 47. 

    *Each IRB that uses an expedited review procedure must adopt a method for keeping all members advised of research proposals which have been approved under the expedited review procedure _________.

    • 45 CFR 46.110; CFR 56.110(c)

    • 45 CFR 46.110(d); 21 CFR 56.110

    • 45 CFR 46.110(c); 21 CFR 56.110(c)

    • 45 CFR 46.110(b); 21 CFR 56.110(c)

    Correct Answer
    A. 45 CFR 46.110(c); 21 CFR 56.110(c)
    Explanation
    Both 45 CFR 46.110(c) and 21 CFR 56.110(c) specify that each Institutional Review Board (IRB) that utilizes an expedited review procedure must have a process in place to keep all IRB members informed of research proposals that have been approved through this expedited review. This requirement ensures transparency and that all IRB members are aware of the research activities being conducted under their oversight.

    Rate this question:

  • 48. 

    Which of the following is the primary responsibility of the Institutional Review Board (IRB) in clinical research?

    • Monitoring the daily operations of the research

    • Protecting the rights and welfare of study participants

    Correct Answer
    A. Protecting the rights and welfare of study participants
    Explanation
    The primary responsibility of the Institutional Review Board (IRB) is to protect the rights and welfare of participants involved in clinical research. The IRB reviews research protocols to ensure that the study is ethically conducted, that risks to participants are minimized, and that informed consent is properly obtained. The IRB's role is crucial in maintaining the ethical integrity of the research process.

    Rate this question:

  • 49. 

    An IND is always required before using an investigational new drug.

    • True

    • False

    Correct Answer
    A. False
    Explanation
    An IND isn't always needed for investigational new drugs. Exceptions include using a marketed drug for an unapproved indication without a clinical investigation, specific Phase 1 studies with approved drugs, or emergencies when no alternative therapy exists. If the drug is used in a clinical investigation to gather data for FDA marketing approval or labeling changes, an IND application is required. This process ensures proper testing and monitoring, protecting participants' safety and generating reliable data on the drug's safety and efficacy.

    Rate this question:

Quiz Review Timeline (Updated): Oct 18, 2024 +

Our quizzes are rigorously reviewed, monitored and continuously updated by our expert board to maintain accuracy, relevance, and timeliness.

  • Current Version
  • Oct 18, 2024
    Quiz Edited by
    ProProfs Editorial Team
  • Feb 25, 2020
    Quiz Created by
    Jessica

Recent Quizzes

What Role in Clinical Research Are You? Quiz What Role in Clinical Research Are You? Quiz
PRA Training - Novartis program - 04 Jun 2020 PRA Training - Novartis program - 04 Jun 2020
FDA: Informed Consent for Clinical Trials! Trivia Questions Quiz FDA: Informed Consent for Clinical Trials! Trivia Questions Quiz
Test your knowledge about SOCRA Test your knowledge about SOCRA
ClinCapture Training - eCRF Design ClinCapture Training - eCRF Design
Novice TMF University Certification Quiz Novice TMF University Certification Quiz
Back to Top Back to top
Advertisement
×

Wait!
Here's an interesting quiz for you.

We have other quizzes matching your interest.